First Wave BioPharma announces acceptance of two abstracts on celiac disease

First Wave BioPharma announced that two abstracts have been accepted for presentation at the 2024 Digestive Disease Week Conference taking place May 18-21, 2024, in Washington, D.C. The first presentation, titled, “A Composite Mucosal Scale for Celiac Disease Encompassing both Morphology and Inflammation,” will highlight VCIEL, a new quantitative composite scale, combining the histologic scales of villus height to crypt depth ratioand density of intraepithelial lymphocytes, designed to enhance the accuracy and precision for measuring small intestinal mucosal health of celiac disease patients with particular benefit for histologic endpoint measurements in clinical trials. The second presentation, titled, “Dynamics of Serologic Change to Gluten in Celiac Disease Patients,” will report research involving the largest database of CeD clinical results and will explore key issues related to the diagnostics of CeD, such as the effects of resuming a gluten-containing diet on seropositivity and the correlation between two different tTG-IgA assays.